Charles River Laboratories International, Inc

Charles River sells primarily to biopharmaceutical companies that outsource early-stage research, safety testing, and selected manufacturing support rather than building all capabilities internally. It also serves biotechnology companies, including emerging and mid-sized firms that need flexible access to specialized scientific infrastructure. Additional customers include agricultural and industrial chemical companies, life science and veterinary medicine companies, medical device and diagnostic firms, consumer product companies, contract research organizations, and contract manufacturing organizations. Universities, teaching hospitals, government agencies, and non-governmental organizations also buy from the company, especially for research and testing services. Demand is tied to customers’ R&D budgets and development pipelines, so spending patterns in pharma and biotech directly affect Charles River’s volumes.

Charles River’s strategy is centered on being a preferred outsourced partner across the early drug discovery and non-clinical development chain. The company emphasizes scientific expertise, regulatory compliance, quality, responsiveness, and flexible solutions that can be scaled across client programs. It also seeks to deepen relationships with large biopharmaceutical customers through preferred provider arrangements and strategic partnerships that encourage cross-selling across the non-clinical portfolio. Management is also focused on disciplined capital allocation, including infrastructure investment, selective acquisitions and divestitures, and share repurchases. In the near term, the company is managing through cautious client spending and a softer demand environment in parts of DSA while supporting growth in RMS and Manufacturing.